Role of Immunotherapy on the Survival of Patients with Pancreatic Cancer

Although pancreatic cancer survival rates have improved over the past few decades, the disease is still considered largely incurable. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 7%. Immunotherapy has revolutionized the treatment landscape of many malignancies, but its therapeutic role in pancreatic cancer (PC) remains unclear.  A recent study conducted in Omaha, Nebraska, USA investigated the impact of immunotherapy on overall survival of PC patients.  The results are interesting and warrant further investigation.

Reference: Journal of Clinical Oncology